ArticleBioprocess and biosystems engineering2026
Chitosan-based hydrogel, along with citrus-derived extracellular vesicles and clove extract: advanced skin wound dressing.
Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant-derived Extracellular vesicles (EVs), particularly those from Citrus limettioides Tan, represent a promising strategy for wound-healing applications. This study investigated the antibacterial and wound-healing efficacy of a chitosan-based hydrogel containing clove extract (CTS/Clo) and EVs through both in vitro and in vivo analyses. Chitosan hydrogels (1.5% and 2%) were formulated with clove extract at concentrations of 0.0156% and 0.0625%. Scanning electron microscopy (SEM), Transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), and drug release profiles showed that the porous structure, combined with a uniform mixture of CTS and Clo, helped the gradual release of Clo. Antibacterial assays against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa confirmed the effectiveness of the hydrogel formulation. Isolated EVs displayed a consistent size distribution and expressed key EV markers. Treatment of human mesenchymal stem cells (hMSCs) and human dermal fibroblasts (HDFs) with the hydrogel and EVs significantly enhanced cell viability (p<0.0001). In an animal model, the combined use of hydrogels with EVs significantly sped up wound closure (up to 95%), increased gene expression (Col1a1, Col3a1, MMP9, VEGFA, TGF-β) related to tissue regeneration, and improved collagen production through collagen deposition (p<0.001) and Col1a1 protein expression.
Indexed as
Identifiers
42726124What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.